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INTRODUCTION
Placental abruption complicates approximately 1% of 
birthsand can be associated with signifi cant perinatal 
morbidity and mortality. Hemorrhage occurs at the de-
cidua-placental interface causing placental separation 
and release of tissue thromboplast into the circulation. 
A large abruption, in particular, may causewidespread 
activation of clotting cascade and rapid consumption 
of clotting factors (1). Rotational thromboelastometry 
(ROTEM®, TEM International GmbH, Munich, Ger-
many) analysis has become an increasingly recognized 
modality forearly detection, dynamic monitoring and 
prompt correction of clotting abnormalitie sassociated 
with major placental abruption (2). Prompt correction 
of hypofi brinogenemia with fi brinogen concentrate 
has already been demonstrated in the context of pla-
cental abruption.When guided by the ROTEM® tests, 
it led to reduced requirements for blood components 
and lower risk of circulatory overload, both of which a 
reparticularly relevant for the obstetric population (3). 
Prothrombin complex concentrate (PCC) is a concen-
trate of either three (II, IX, X) or four (II, VII, IX, X) 
clotting factors. In the obstetric population, its use has 
mostly been restricted to cases where there is either 
congenital or acquired defi ciency of specifi c coagula-
tion factors (4). In massive obstetric hemorrhage, PCC 
has been used with no ROTEM® guidance (5). We 
present a hitherto undescribed case of ROTEM®-guid-
ed PCC usage for prompt management of severe coag-
ulopathy associated with minor placental abruption. 
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Placental abruption can cause signifi cant hemorrhage and coagulopathy that can progress rapidly due to consumption and 
depletion of clotting factors. Rapid detection and treatment of hypofi brinogenemia is essential in the evolving clinical and 
hematologicmilieu. The use of ROTEM® allows a dynamic monitoring of coagulopathy. So far, only fi brinogen concentrate 
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prothrombin complex concentrate therapy, as well as diagnostic and therapeutic considerations of ROTEM® - guided test 
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CASE REPORT
A healthy 41-year-old, 75 kg, gravida 4, with 3 previous 
spontaneous vaginal deliveries, was admitted to the la-
bor ward at 38 weeks of gestation due to vaginal bleed-
ing. Ultrasound examination revealed a minor placental 
abruption. Her blood pressure was 115/75 mmHg, heart 
rate 85 beats per minute and oxygen saturation in room 
air 97%. She had 18-gauge intravenous access secured 
and laboratory blood workup performed revealing he-
moglobin of 115 g L-1 and platelet count of 16x109 L-1. 
Since the fetal heart rate was reassuring, vaginal delivery 
was undertaken aft er artifi cial membrane rupture and 
stimulation with oxytocin. Th e labor was precipitous 
with delivery of a male infant with APGAR score 9/93 
hours later. Aft er completion of the labor third stage 
(t=0 min), uterine atony was diagnosed, and the anes-
thetic team was called into the delivery room. As per in-
stitutional practice, general anesthesia was induced with 
2 mg of midazolam and 50 mg of ketamine for manual 
exploration of the uterus due to suspected retained pla-
centa. Subsequently, a second IV access was established 
followed by consecutive administration of oxytocin in 
drip infusion, methylergonovine maleate (Methergine) 
and 15 methyl F2 alpha prostaglandin (Prostin 15M) 
intramuscularly. At the same time, abnormal vaginal 
bleeding was apparent with no clots formed on the 
drapes. Th is raised suspicion of consumptive coagu-
lopathy associated with placental abruption, prompting 
the activation of the local hemorrhage protocol starting 
with intravenous administration of tranexamic acid 2 g, 
fi brinogen concentrate 2 g. Haemocompletan, CSL Beh-
ring, PA, USA) while requesting 4 units of fresh frozen 
plasma (FFP), 4 units of packed red blood cells (RBC) 
and 2 pools of platelets. Simultaneously, the ROTEM® 
guided tests were ordered from the central laboratory. 
At an estimated ongoing blood loss of approximately 
1000 mL, 1500 mL of crystalloids and colloids, and 2 
units of RBC were administered to the patient. 
Twenty minutes aft er requesting the ROTEM® test 
(t=45 min), the working diagnosis was confi rmed by 
the FIBTEM trace of fl at line and EXTEM clotting 
time (CT) of 208 seconds (Figure 1A). Fibrinogen 
concentrate 6g and PCC (Octaplex®, Octapharma, 
Austria) 1000 IU were immediately administered and 
second ROTEM® ordered, followed by infusion of an-
other 2 units of RBC. Th e results of second ROTEM® 
obtained 20 min later (t=90min) showed improved 
but still abnormal coagulation with FIBTEM (A10) of 
5 mm, EXTEM (CT) of 76 seconds and EXTEM (A5) 
of 20 mm (Figure 1B); so, fi brinogen concentrate 2 g 
was given, in addition to 3 units of FFP and 2 pools 
of platelets. To maintain uterine tone, 400 μg of miso-
prostol was given rectally, aft er which vaginal bleed-
ing stopped. Th e parturient was hemodynamically 
stable throughout the procedure. Th e estimated blood 
loss was 2300 mL. Th e parturient stayed in the deliv-
ery unit for another three hours for close observation 
aft er which she was transferred to the high-depen-
dency maternity unit. Last ROTEM® (t=6 h) showed 
complete normalization of hemostasis with FIBTEM 
(A10) of 13 mm, EXTEM CT of 54 seconds and EX-
TEM (A10) of 58 mm (Figure 1C). Her hemoglobin-
was 94 g L-1and platelets 116x109L-1. Four days later, 
the parturient was discharged from the hospital with 
no complications recorded as a result of hemorrhage 
or hemostatic therapy thereaft er. 
Fig.1. ROTEM® tests results: initial ROTEM®test demonstrating fi brinolysis associated with placental abruption (A); second 
ROTEM® test aft er 8 g of fi brinogen and 1000 IE of prothrombin complex concentrate (PCC) were administered resulting in 
FIBTEM A5 increase and EXTEM CT reduction (B); normalization of ROTEM® test aft er 2 additional grams of fi brinogen, 4 
units of fresh frozen plasma (FFP) and 2 units of platelets (C). CT, clotting time; CFT, clot formation time; α, alpha angle; A10 
amplitude at 10 min aft er CT; A20 amplitude at 20 min aft er CT; MCF, maximum clot fi rmness (maximal amplitude); ML, 
maximum lysis
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DISCUSSION
Th e present case describes prompt and eff ective man-
agement of severe coagulopathy associated with pla-
cental abruption with a combination of prothrombin 
complex and fi brinogen concentrates under ROTEM® 
guidance, demonstrating the possible and safe applica-
tion of PCC in obstetrics. 
Our report reaffi  rms the fi ndings reported by McNamara 
et al., that coagulopathy associated with placental abrup-
tion progresses rapidly resulting in very low FIBTEM A5, 
EXTEM A5 and prolonged EXTEM CT with high dos-
ages of fi brinogen concentrate and platelet transfusion 
needed to compensate for clotting factor consumption 
(2). In our patient, the total amount of fi brinogen con-
centrate injected was 10g, i. e. 2g aft er suspicion of coag-
ulopathy and 8 g aft er obtaining ROTEM®-guided tests. 
Guided by the latest recommendations on managing 
postpartum hemorrhage (PPH) and the initial FIBTEM 
trace of fl at line, we injected 6 g of fi brinogen concen-
trate in order to raise plasma fi brinogen level above 2 
g L-1(6). Th e fact that second FIBTEM A5 reached only 
5 mm (plasma fi brinogen approximately 1 g L-1) most 
likely indicated ongoing fi brinolysis, having required 
additional 2 g of fi brinogen concentrate, which together 
with 1 L of FFP (plasma fi brinogen approximately 2 g 
L-1) resulted in fi nal FIBTEM A5 of 13 mm (plasma fi -
brinogen approximately 2.5g L-1). Th is approach of cyclic 
ROTEM® assessment, treatment and reassessments al-
lowed a more appropriate fi brinogen concentrate dosing, 
particularly in a patient with consumptive coagulopathy 
where the prediction of the amount needed on the ba-
sis of a single clotting assessment is very diffi  cult due to 
rapidly changing coagulation profi le (7). Nevertheless, 
hemostatic changes in placental abruption diff er from 
those obtained in women who bleed due to uterine atony 
or surgical or obstetric trauma causes at similar levels of 
estimated blood loss. Placental abruption and placenta 
accrete are usually associated with the lowest fi brino-
gen levels at ‘presentation’ (median 0.7g/L and 1.5 g/L, 
respectively), while obstetric trauma is associated with 
the highest fi brinogen (median 2.7 g/L). Th is indicates 
that coagulopathy of massive obstetric hemorrhage dif-
fers signifi cantly depending on its cause, and thus more 
targeted transfusion strategies are needed depending on 
the etiology (8).
When the EXTEM CT is more than 100 seconds, FFP 
is indicated to replace clotting factors other than fi -
brinogen (2). Nevertheless, the use of PCC enabled 
faster correction of hemostasis while allowing the ob-
stetric team to focus on resolving persistent uterine 
atony (7). Th e benefi ts of PCC administration extend 
well beyond bleeding control. PCC does not require 
cross-matching and was rapidly administered with 
minimal risk of infection, transfusion-related circula-
tory overload, or acute lung injury. Also, with a small 
administration volume, PCC allowed maintaining he-
modynamic status in our patient with smaller amount 
of blood products, decreasing the risk of volume over-
load and signifi cant dilution of plasma constituents 
particularly favorable for a parturient (9).
Prothrombin complex concentrate used in our case 
was a concentrate of four clotting factors containing 
factors II, VII, IX, X and a low dose of coagulation in-
hibitors such as protein C, protein S, antithrombin and 
heparin. Th is, however, does not eliminate the risk of 
thromboembolic complications because in PCC the 
level of key inhibitor antithrombin is much lower than 
the levels of coagulation factors (10), suggesting cau-
tion particularly in obstetric patients with a history of 
thrombosis or inherited or acquired thrombophilia. 
Th e reports on PCC usage in massive obstetric hem-
orrhage are scarce because signifi cant derangements 
in the ROTEM®-EXTEM parameters are rare or a late 
feature of massive blood loss. At present, EXTEM CT 
represents the best means of assessing whether the res-
toration of thrombin generation is needed and should 
only be interpreted aft er clot fi rmness has been reinsti-
tuted (FIBTEM A5>10 mm), since a decreased quality 
of the fi brin-based clot due to low fi brinogen level can 
be a common cause of prolonged CT (10). As a result, 
further research on the potential of EXTEM CT nor-
malization aft er the clot fi rmness has been reinstituted 
is needed in order to prevent unnecessary FFP/PCC 
administration. For such treatment approach, a bed-
side ROTEM® is required. 
In our patient, platelet transfusion was given with an 
EXTEM A10 of 37 mm (second ROTEM® test), which 
is in line with the trauma algorithm where an EXTEM 
A10 cut off  value of 40 mm has been selected. Th e 
PPH algorithm is in fact very similar to the trauma 
algorithm but takes into account the shift  in fi brino-
gen and FIBTEM reference ranges during pregnancy 
and the diff erent FIBTEM A5 cut-off  and target values 
determined for this setting (11).
In conclusion, this case report demonstrates the safe 
use of PCC in major obstetric hemorrhage. Neverthe-
less, uncertainty regarding PCC usage in obstetrics 
still exists and it is primarily related to its increased 
thrombogenicity. Larger studies on PPC effi  cacy and 
safety in managing severe obstetric coagulopathy are 
therefore warranted. 
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Abrupcija posteljice može uzrokovati veći gubitak krvi i potrošnu koagulopatiju koja vodi do smanjenja ili nedostatka 
faktora koagulacije. Brzo otkrivanje nedostatka fi brinogena i ciljano usmjerena hemostatska terapija neophodni su za 
učinkovitu hemostazu kod abrupcije placente. Korištenje ROTEM® omogućuje dinamičko praćenje koagulopatije. Do sada 
je u literaturi opisano liječenje teške koagulopatije zbog abrupcije posteljice samo koncentratom fi brinogena. Prikazujemo 
višerotkinju u dobi od 40 godina kod koje je došlo do abrupcije posteljice s teškom koagulopatijom, gdje je za ciljano lije-
čenje korištena kombinacija protrombinskog kompleksa i koncentrata fi brinogena. U članku raspravljamo o potencijalnim 
prednostima i nedostatcima terapije koncentratom protrombinskog kompleksa, kao i o dijagnostičkim i terapijskim moguć-
nostima ROTEM®-a.
Ključne riječi: koagulopatija, abrupcija posteljice, kombinacija protrombinskog kompleksa, koncentrat fi brinogena, 
 krvarenje u opstetriciji
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